Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00203190
Other study ID # SDS/TOP-CL/01/CAPSS-322
Secondary ID 080-19000-H56501
Status Terminated
Phase Phase 4
First received September 12, 2005
Last updated January 22, 2009
Start date September 2004
Est. completion date June 2006

Study information

Verified date January 2009
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax®. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period.


Recruitment information / eligibility

Status Terminated
Enrollment 60
Est. completion date June 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subjects between the ages of 18 and 65 with a diagnosis of cluster headache (episodic or chronic) as defined by the International Classification of Headache Disorders (2nd edition)

- Subjects must have a lifetime prevalence of at least 2 prior cluster cycles.

- Subjects must experience one or more attacks/ day during baseline period

- Subjects must have a typical cluster period lasting at least 8 weeks. Subjects must present in active cluster period and the expected remaining duration of the cluster cycle must be at least 8 weeks from Baseline visit.

- Subjects with other headache types are eligible provided the subject is able to differentiate these headaches from cluster headaches.

- Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential

- Subject has negative urine pregnancy test prior to study entry, if female of child-bearing potential

- Subject is able to understand and comply with all study requirements

- Subject provides written informed consent prior to any screening procedures being conducted

Exclusion Criteria:

- Women who are pregnant or lactating

- Subjects who, in the investigators opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial

- Subjects who require a change in medication or existing regimen of medication for the prophylaxis of cluster in the 4 weeks prior to Baseline visit and for the duration of the trial

- Subjects who have cluster headaches that typically exceed 4 hours

- Subjects who have used the following medications/ treatments from four weeks prior to Baseline visit: corticosteroids and nerve blocks.

- Subjects using any drug which might interact adversely with, or interfere with the action of, the study medication (e.g., carbonic anhydrase inhibitors)

- Subjects who have failed an adequate trial of topiramate for cluster headaches due to lack of efficacy or adverse events, as determined by the investigator

- Subjects with a history of nephrolithiasis.

- Subjects who are allergic to or have shown hypersensitivity topiramate or agents similar to topiramate

- Subjects who abuse opioids as determined by investigator

- Subjects with a history of significant drug or alcohol abuse within the past year

- Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Topiramate


Locations

Country Name City State
United States Jefferson Headache Center Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Thomas Jefferson University Ortho-McNeil Neurologics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the average daily frequency of moderate or severe attacks between baseline period to the period of day 14 to 56.
Secondary Change in the average daily frequency of any attacks from the baseline period through the entire treatment period.
Secondary Change in the average daily duration of any attacks from the baseline period through the entire treatment period.
Secondary Change in the average daily attack severity from baseline period through the entire treatment period.
Secondary Change in the average daily frequency of any attacks from the baseline period to each week during the treatment period.
Secondary Change in the average daily duration of any attacks from the baseline period to each week during the treatment period.
Secondary Change in the average daily attack severity from the baseline period to each week during the treatment period.
Secondary Time to the first week from the baseline period with a 50% reduction in average daily frequency of moderate or severe attacks.
Secondary Change in use of acute and rescue medications from the baseline period through the entire treatment period.
See also
  Status Clinical Trial Phase
Recruiting NCT05264714 - Cluster Headache Treatment With Rimegepant Phase 2
Completed NCT01677026 - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated NCT04570475 - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache Phase 3
Completed NCT04066023 - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches Phase 2/Phase 3
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT02019017 - Botox Injection in Treatment of Cluster Headache Phase 1/Phase 2
Completed NCT05153876 - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting NCT05324748 - Repeated GON Injections in CCH Phase 3
Completed NCT02782533 - DBS of the Third Ventricle for Cluster Headache and Obesity N/A
Completed NCT04179266 - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Phase 1/Phase 2
Recruiting NCT04406259 - Atrioventricular Block and Cluster Headache (SEVA) Phase 4
Recruiting NCT06206772 - Resting State Functional Connectivity in Cluster Headache
Recruiting NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Phase 3
Not yet recruiting NCT05857098 - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting NCT02910323 - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated NCT00458770 - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks N/A
Completed NCT00662935 - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) N/A
Active, not recruiting NCT03511846 - Pain Biomarker Study Phase 1
Completed NCT00184587 - Prophylactic Treatment of Episodic Cluster Headache Phase 2
Not yet recruiting NCT06277063 - nVNS for the Prevention and Treatment of Primary Headache N/A